IRD

Quarterhill Provides Update to Q4 and Fiscal 2021 Financial Results Announcement

Retrieved on: 
Tuesday, March 8, 2022
ETC, TSX, Intelligent transportation system, Industry, Intellectual property, International Road Dynamics, Solution, LLC, Acquisition, IRD, ITS, Communications satellite, Retail, Civil engineering

ET on March 22, 2022, until 11:59 p.m.

Key Points: 
  • ET on March 22, 2022, until 11:59 p.m.
  • ET on March 29, 2022, at: 1.888.390.0541 (Toll Free North America) or 1.416.764.8677.
  • Quarterhill is a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (ITS) industry, as well as, through its Wi-LAN Inc. subsidiary, a leader in Intellectual Property licensing.
  • Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF.

Quarterhill Hires Stout as Financial Advisor for the WiLAN Strategic Review Process

Retrieved on: 
Monday, March 7, 2022
Investment banking, Perception, ETC, TSX, Intelligent transportation system, Industry, Stout, Forward-looking statement, Risk, Intellectual property, News, Director, International Road Dynamics, Solution, LLC, Board, Sale, COVID-19, Disease, Acquisition, Patent, IRD, WiLAN, ITS, CEO, AIF, Review, Technology, Coronavirus, Financial adviser

TORONTO, March 7, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), announces that the special committee to the Board of Directors of the company has hired Stout as its financial advisor for the WiLAN strategic review process, which was previously announced on December 15, 2021.

Key Points: 
  • TORONTO, March 7, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), announces that the special committee to the Board of Directors of the company has hired Stout as its financial advisor for the WiLAN strategic review process, which was previously announced on December 15, 2021.
  • Stout professionals have also advised on carve outs of tens of thousands of non-core IP assets during and post M&A.
  • There can be no assurance that this strategic review process will result in the completion of any transaction or other alternative.
  • The special committee of the Board, working closely with Quarterhill's CEO, Bret Kidd, will oversee this strategic review of WiLAN over the coming months.

IRD Announces $5.5 Million Agreement with the Indiana DOT

Retrieved on: 
Monday, March 7, 2022
Perception, TSX, VDS, Intelligent transportation system, Software, Industry, City, Forward-looking statement, Risk, OTCQX, Intellectual property, News, Solution, Indiana Department of Transportation, COVID-19, Disease, IRD, ITS, CEO, Maintenance, AIF, Engineering, Review, Partnership, Coronavirus, Agreement, Transport, INDOT

Under the Agreement, IRD will be issued task orders to provide electronic equipment, software, and services required to build, reconstruct, test, calibrate, and maintain Weigh-in-Motion ("WIM") and Virtual Weigh-in-Motion ("VWIM") systems for INDOT.

Key Points: 
  • Under the Agreement, IRD will be issued task orders to provide electronic equipment, software, and services required to build, reconstruct, test, calibrate, and maintain Weigh-in-Motion ("WIM") and Virtual Weigh-in-Motion ("VWIM") systems for INDOT.
  • IRD will assist INDOT in defining the solution for each site based on the type of traffic data to be collected at that location.
  • Mr. Rish Malhotra, IRD President and CEO, noted, "IRD is proud to be selected by the Indiana Department of Transportation for this important project.
  • IRD is a dynamic technology company engaged in developing key components and advanced systems for the next generation of transportation networks.

Quarterhill to Announce Q4 and Fiscal 2021 Financial Results

Retrieved on: 
Thursday, February 24, 2022
TSX, Intellectual property, IRD, Intelligent transportation system, Industry, LLC, ETC, Acquisition, International Road Dynamics, ITS, Solution, Communications satellite, Retail, Civil engineering

ET on March 10, 2022, until 11:59 p.m.

Key Points: 
  • ET on March 10, 2022, until 11:59 p.m.
  • ET on March 17, 2022, at: 1.888.390.0541 (Toll Free North America) or 1.416.764.8677.
  • Quarterhill is a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (ITS) industry, as well as, through its Wi-LAN Inc. subsidiary, a leader in Intellectual Property licensing.
  • Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF.

Biologica in Partnership With JS Group and Medipak Organized a Ceremony to Mark the Handing Over of 35,000+ COVID-19 Rapid Antigen Test Kits

Retrieved on: 
Friday, February 18, 2022
COVID, School, Alternative, Centre for Interactive Research on Sustainability, Health, Safety, Technology, Student, Mental health, Lists of television programs, Bill & Melinda Gates Foundation, Partnership, Child, Government, IRD, Jahangir Siddiqui & Co., Research, Disease, COVID-19, GLOBE, Organization, Pharmaceutical industry, Vaccine

KARACHI, Pakistan, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Karachi: Committed to giving back to society, Biologica in partnership with JS Group and Medipak organized a ceremony to mark the handing over of 35,000+ COVID-19 Rapid Antigen Test Kits to Interactive Research and Development (IRD), funded by the Bill and Melinda Gates Foundation.

Key Points: 
  • KARACHI, Pakistan, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Karachi: Committed to giving back to society, Biologica in partnership with JS Group and Medipak organized a ceremony to mark the handing over of 35,000+ COVID-19 Rapid Antigen Test Kits to Interactive Research and Development (IRD), funded by the Bill and Melinda Gates Foundation.
  • The ceremony was attended by Faisal Ismail, CEO-Biologica, Naveed Khalid Chowdhry, CEO-Medipak, Aneeta Pasha, Country Director-IRD Pakistan along with other senior officials.
  • We are also excited to announce that the local production of COVID-19 Rapid Antigen Test Kits will be commencing soon in collaboration with Medipak and Mologic/Global Access Diagnostic UK, a leading innovator in rapid diagnostic technology.''
  • This initiative will contribute towards healthcare, provide employment opportunities, and have great export potential in line with the vision of the Government of Pakistan.

ETC Signs Contract to Implement and Operate Express Lanes for the Alameda County Transportation Commission

Retrieved on: 
Friday, February 18, 2022
Online, Algorithm, LLC, ITS, Interstate 680, Perception, Forward-looking statement, Intelligent transportation system, Review, Solution, Transport, AIF, Big data, GLOBE, Risk, Technology, Interstate Highway System, AET, Intellectual property, Commission, KPI-driven code analysis, ETC, Maintenance, Express lanes, OTCQX, Acquisition, Disease, IRD, Machine learning, Industry, Coronavirus, COVID-19, News, TSX, International Road Dynamics, Software as a service, MOMS, Road, Renewable energy, County

The contract is subject to customary terms and conditions and valued at ~US$4M for the implementation, with amendments for maintenance to follow.

Key Points: 
  • The contract is subject to customary terms and conditions and valued at ~US$4M for the implementation, with amendments for maintenance to follow.
  • Over the short term of the integration contract, ETC will reuse existing infrastructure along with the integration of ETCs latest all-overhead lane solution to launch the express lanes into revenue service in 2022.
  • For more information, visit www.quarterhill.com
    The Alameda County Transportation Commission (Alameda CTC) serves as the congestion management agency and transportation authority for the County of Alameda and is responsible for the planning, programming and allocation of federal, state, regional and local funding for transportation improvements throughout the County.
  • Its mission is to plan, fund and deliver transportation programs and projects that expand access and improve mobility to foster a vibrant and livable Alameda County.

ETC Signs Contract to Implement and Operate Express Lanes for the Alameda County Transportation Commission

Retrieved on: 
Friday, February 18, 2022
Online, Algorithm, Quarterhill, ITS, Perception, Forward-looking statement, Intelligent transportation system, Review, Solution, Transport, AIF, Big data, Risk, Technology, Interstate Highway System, AET, Intellectual property, Commission, KPI-driven code analysis, ETC, Maintenance, Express lanes, Acquisition, Disease, IRD, Machine learning, Industry, Coronavirus, COVID-19, News, TSX, International Road Dynamics, Software as a service, LLC, MOMS, County

The contract is subject to customary terms and conditions and valued at ~US$4.0 million for the implementation, with amendments for maintenance to follow.

Key Points: 
  • The contract is subject to customary terms and conditions and valued at ~US$4.0 million for the implementation, with amendments for maintenance to follow.
  • "ETC is thrilled to continue serving as Alameda CTC's trusted technology provider," stated ETC's Chief Executive Officer Kevin Holbert.
  • For more information, visit www.quarterhill.com
    The Alameda County Transportation Commission (Alameda CTC) serves as the congestion management agency and transportation authority for the County of Alameda and is responsible for the planning, programming and allocation of federal, state, regional and local funding for transportation improvements throughout the County.
  • Its mission is to plan, fund and deliver transportation programs and projects that expand access and improve mobility to foster a vibrant and livable Alameda County.

Nanoscope Therapeutics CEO Sulagna Bhattacharya Elected to BIO Emerging Companies Section Governing Board

Retrieved on: 
Thursday, February 17, 2022
RP, Patient, Atomic de Broglie microscope, Sulagna Panigrahi, CEO, Retinitis pigmentosa, Biotechnology Innovation Organization, IND, Company, Leadership, Therapy, Kepler-86, Biotechnology, MCO, FDA, Policy, BIO, IRD, Growth, Industry, Organization, Pharmaceutical industry, Stargardt disease

DALLAS, Feb. 17, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the Biotechnology Innovation Organization (BIO) Emerging Companies Section Governing Board .

Key Points: 
  • DALLAS, Feb. 17, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the Biotechnology Innovation Organization (BIO) Emerging Companies Section Governing Board .
  • Washington D.C.-based BIO is the world's largest Biotechnology advocacy organization representing companies, academic institutions, and local biotechnology centers across the U.S. and globally.
  • "We are very pleased to have Sulagna join our board," said Dr. Michelle McMurry-Heath, President & CEO of BIO.
  • BIO also produces the BIO International Convention ,the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings globally.

Inside Research and Development (IRD) Market Opportunities Service 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 11, 2022
Professional Services, Other Professional Services, Automation, IRD, Health, Microsoft PowerPoint, Research, TOE, Biotechnology, Intelligence, Electronics, Creative industries

The "Inside R&D TechVision Opportunity Engine" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inside R&D TechVision Opportunity Engine" newsletter has been added to ResearchAndMarkets.com's offering.
  • The Inside Research and Development (IRD) TechVision Opportunity Engine (TOE) covers global innovations that are in research and development across virtually all technology areas.
  • This monthly PowerPoint profiles 20 innovations every month in PowerPoint format, which helps in highlighting innovation features, value propositions, industry impacts and other pertinent details such as commercialization strategies and marketing efforts.
  • The TOE provides intelligence on emerging technologies across all industry verticals, enabling decision-makers, strategists, venture capitalists, technology developers and others in the technology ecosystem to gauge investment, research and development opportunities.

ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer

Retrieved on: 
Wednesday, February 9, 2022
Retinitis pigmentosa, GLOBE, Retina, Venture round, Fas, CDO, Death, Retinal detachment, International Management Institute, New Delhi, Severe cognitive impairment, Doctor of Philosophy, Research, ONL, Company, Ophthalmology, SynCo Bio Partners, FT, ANN, IND, Therapy, GA, FDA, Patient, Cell death, Neuroprotection, Glaucoma, Technology, Vance DeGeneres, OAG, Geographic atrophy, Master of Pharmacy, IRD, AMD, MBA, Pharmaceutical industry, Biochemistry, Marketing

ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer.

Key Points: 
  • ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer.
  • Sushantas experience in leading ophthalmology development, particularly in our target disease areas of interest, will be critical as we continue to advance ONL1204 across three key indications, said David Esposito, Chief Executive Officer of ONL Therapeutics.
  • I am thrilled to join the ONL Therapeutics team with its mission of bringing neuroprotection innovation to patients suffering from serious retinal diseases, commented Dr. Mallick.
  • ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease.